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Chemotherapy is the most effective treatment for inoperable patients (70%) affected with non-small cell 
lung cancer (NSCLC). The early detection of tumour progression is mandative in order to promptly shift 
these patients towards salvage or supportive therapy. 
The present authors investigated the clinical value of a panel of tumour markers, elaborated by means 
of discriminant analysis, as a follow-up indicator for the detection of tumour progression. The serum 
levels of tissue polypeptide antigen (TPA), CYFRA-21.1, neuron-specific enolase (NSE) and carcino- 
embryonic antigen (CEA) were determined before chemotherapy and after three cycles of treatment. 
Discriminant analysis generated a formula (canonic variable) which correctly classified the 87.8% of the 
74 subjects (86.1% of the 36 progressive diseases and 89.5% of 38 non-progressive diseases). 
This approach produces an algorithm able to calculate a progression score in NSCLC patients which 
can be helpful for following-up care and therapy control of these patients. 
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Introduction 
Adenocarcinoma (LADC), squamous cell carci- 
noma (SQCLC) and large cell carcinoma 
(LCLC) have identical biological behaviour and 
therapeutical approaches, and are collectively 
termed non-small cell lung cancer (NSCLC). 
This accounts for 85% of all newly diagnosed 
lung cancers (1). Although surgery offers the best 
probability of cure for NSCLC, less than 30% 
of these patients are candidates for radical resec- 
tion (2). In subjects with locally advanced and/ 
or disseminated NSCLC and/or with medical 
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contraindications to surgery, chemotherapy 
represents the only treatment modality. 
Unfortunately, the results of combination 
chemotherapy in NSCLC remain disappointing 
(the response rates ranging between 30 and 50%) 
(3). Furthermore, multidrug combinations have 
shown only a slight advantage when compared 
with best supportive care, but at the expense 
of a higher toxicity (4,5). Therefore, patients 
treated with chemotherapy need to be carefully 
monitored in order to prevent continuation of 
ineffective treatments. 
In addition to standard restaging procedures 
(6) the availability of simple laboratory tests 
that reflect the changes of the total tumour load 
may be helpful. 
Serum tumour markers have been used in lung 
cancer for monitoring treatment and predicting 
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TABLE 1. Clinical characteristics of the patients employed to (a) generate and (b) validate 
the canonic variable 
Sex Age (years) 
Stages 
Histology Patients M/F Median Range I II IIIa IIIb IV 
(4 
LADC 14 7/l 63 41-80 0 0 3 5 6 
SQCLC 26 15/11 62 45-73 4 3 6 4 9 
LCLC 3 2/l 65 63-68 0 0 2 0 1 
@I 
LADC 12 616 59 46-78 1 1 2 3 5 
SQCLC 16 1016 63 46-74 0 3 3 5 5 
LCLC 3 2/l 66 61-67 0 1 1 0 1 
LADC, adenocarcinoma; SQCLC, squamous cell lung carcinoma; LCLC, large cell lung 
carcinoma. 
relapse (7). Otherwise, the literature does not 
report clear indications as to the clinical value of 
single tumour marker determination during 
follow-up of patients with NSCLC (8-10). 
Recently, many studies have shown that the 
employment of two or more markers, used in 
combination as a marker panel, can improve 
their clinical value for monitoring of NSCLC 
patients (1 l-l 3). Furthermore, computerization 
has made possible the employment of statistical 
methods to evaluate the role of the different 
markers in relation to each other and weighted 
together. 
This study represents an attempt to optimize 
the use of some commonly investigated tumour 
markers (tissue polypeptide antigen, TPA; 
CYFRA-21.1; neuron-specific enolase, NSE; 
and carcino-embryonic antigen, CEA) elabo- 
rated by means of discriminant analysis, in order 
to distinguish progressive disease (PD) from 
non-progressive disease (NPD) in treated 
NSCLC patients at the time of restaging. 
Patients and Methods 
PATIENT POPULATION 
From July 1993 to June 1994, a group of 43 
consecutive, unselected and previously untreated 
patients with inoperable NSCLC was evaluated. 
A second group of 31 patients affected with 
inoperable NSCLC was subsequently enrolled to 
validate the discriminant ability of the canonic 
variable (CV) generated in the first group. 
Pre-treatment staging for all patients was 
performed according to the guidelines of the 
American Joint Committee on Cancer (14). 
Table l(a,b) shows the main clinical character- 
istics of the patients of the two groups. No 
differences were found between the two groups 
of patients. Candidacy for surgical resection was 
excluded on the basis of tumour stage, pul- 
monary function and comorbid disease. Patients 
with advanced NSCLC or medical contraindica- 
tions to surgery were referred to chemotherapy. 
All patients received chemotherapy with MVP 
(mitomycin, 10 mg m - 2 i.v. on Day 1, vindesine 
3 mgmp2 on Days 1 and 15, and cisplatin 75 mg 
m p2 on Day 1) every 4 weeks. After the third 
cycle of chemotherapy, the patients were 
re-assessed with chest X-ray, radionuclide bone 
scan and computed tomography of the brain, 
chest and abdomen. 
Tumour volume was defined by multiplying 
the largest diameter by the greatest perpendicu- 
lar diameter on chest X-ray. 
A complete response (CR) was defined as 
complete disappearance of all objective clinical 
evidence of disease; a partial response (PR) was 
defined as a decrease in tumour volume by 
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greater than 50%; a minor response (MR) was a 
decrease by 20-50% of pre-treatment size; no 
change (NC) was a ~20% decrease in tumour 
size; and progressive diseases (PD) was any 
increase in tumour volume or the onset of new 
lesions. Response to chemotherapy was assessed 
without knowledge of tumour marker levels. 
TUMOUR MARKERS 
The serum tumour marker levels were deter- 
mined before chemotherapy and at the time of 
restaging. The sera of the patients, obtained by 
venipuncture and stored at - 40°C were tested 
for CEA (Sorin Biomedica, Saluggia, Italy), 
TPA (Byk Sangtec, Cormano, Italy), NSE (CIS 
Diagnostici, Vercelli, Italy) and CYFRA-21.1 (a 
cytokeratin antigen, CIS Diagnostici, Vercelli, 
Italy). Samples with evident haemolysis were not 
included because they were shown to give 
increased assay values (15). The tests, based on 
radioimmunoassay techniques, were evaluated 
in duplicate according to the manufacturers’ 
instructions. 
STATISTICAL ANALYSIS 
Non-parametric tests were used for the single 
markers due to their distributions. The Kruskall- 
Wallis one-way analysis of variance was used to 
compare the different groups, and the Spearman 
Rank correlation test was used to calculate the 
correlation coefficients. 
Logarithmic transformation was needed for 
the value of each tumour marker to normalize its 
distribution. 
Discriminant analysis was performed on a 
computer using the BMDP program (BMDP 
statistical software, University of California, 
U.S.A., P7M module) (16,17). 
This multiparametric test permits the gener- 
ation of CV that can separate two groups. The 
CV is a score obtained by adding together the 
levels of the variables selected, multiplied by 
appropriate coefficients, negative or positive. 
The CV associates the different discriminant 
abilities of the various parameters, contributing 
to the final overall classification. The program 
selects the most useful parameters for the maxi- 
mum discrimination, eliminating the highly cor- 
related variables. The CV is standardized (by 
means of a constant number) to zero when the 
patient cannot be classified in a group. 
Since the formula directly derives from the 
data of the group selected, overestimation can- 
not be ruled out (18). To overcome this problem, 
the authors used; (1) a jack-knifed approach (i.e. 
each patient was evaluated by a CV obtained 
after exclusion of the same patient’s data); 
and (2) a validation group (a second group 
of patients, enrolled subsequently and not 
employed to generate the first algorithm). 
Results 
A group of 43 NSCLC patients (generation 
group) [Table l(a)] was evaluated before chemo- 
therapy and at the time of restaging. Twenty- 
three PDs and 20 NPDs (two CRs; two PRs, two 
MRs and 14 NCs) were found. This group was 
used to generate a CV on the basis of the tumour 
marker levels measured before therapy and at 
the time of restaging to evaluate which tumour 
markers could be able to distinguish, combined 
in a single score, the patients with PD from those 
with NPD. 
Table 2(a) reports the differences between 
the median levels and ranges observed for the 
individual variables in the generation group 
subdivided for PD or NPD. For brevity, only 
the variables selected during the subsequent dis- 
criminant analysis are shown. These discrimi- 
nant factors were represented by the serum CEA 
and TPA levels, measured at the time of restag- 
ing, and the NSE and TPA ratios calculated by 
dividing the post-treatment by the pre-treatment 
levels, respectively. It must be emphasized that 
all marker values were significantly modified 
when comparing PD and NPD groups. 
The formula to calculate the CV score was as 
follows: CV= (Ln CEA x 0.11684) + (Ln TPA x 
0.6446 1) + (Ln TPA-ratio x 0.6595 1) + (Ln NSE- 
ratio x l-01991) - 3.50395, where all the coef- 
ficients are positive because their increases 
augment the progression probability. 
Tables l(b) and 2(b) present the data of 
another group of 3 1 NSCLC patients (validation 
group) collected after the elaboration of the 
discriminant analysis. In this validation group, 
all markers were significantly modified between 
PD and NPD (the only exception was the 
post-treatment CEA). 
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TABLE 2. Medians and ranges of the variables selected (a) generation group and (b) 
validation group 
CEA TPA 
(ng ml - ‘) (U ml-l) 
TPA-R NSE-R 
(4 
PD (23) 
NPD (20) 
Median 6.8 268 1.7 1.1 
Range 0.5-100 47-3000 0.3-5.8 0.5-2.1 
Median 3.45 67.5 1.1 0.9 
Range 04-48 10414 0.1-1.8 0.4-2.3 
P 0.014 0.000048 0.000028 0.011 
@I 
PD (13) 
NPD (18) 
Median 11 199 1.3 1.5 
Range 2.1-70 29-l 178 0.5-3.8 0.7-3.9 
Median 3.9 70.5 0.68 1.04 
Range 2.1-22 16-552 0.1-1.7 0.5-3.1 
P 0.09 0.019 0.003 0.03 
PD, progressive disease; NPD, non-progressive disease; CEA, carcino-embryonic antigen; 
TPA, tissue polypeptide antigen; NSE, neuron-specific enolase. Patient numbers are 
reported in parentheses. Post-treatment/pre-treatment ratio values are indicated by -R 
after the marker name. 
Considering all the patients of the two groups 
together, only a low correlation coefficient was 
recorded between post-treatment CEA vs. post- 
treatment TPA (R= Q-25; P= 0.03). Carcino- 
embryonic antigen and TPA showed a high 
correlation with CYFRA-21.1 (data not shown). 
Figure 1 shows the individual CV values for 
each patient, and patients’ classifications at the 
time of restaging. The rate of correct classifi- 
cation was 88.4% for the generation group and 
87.1% for the validation group. The overall 
classification was 87.8%. Figure 1 shows the 
lack of differences between the generation and 
validation groups. 
No errors were observed for the two CRs and 
the five PRs. Only one error was found from six 
MRs (16.6%) and five of the 36 PDs (13.8%). 
The CR+PR CV levels, calculated on 74 
patients, were statistically different when com- 
pared to MR+NC subjects (P=O*O3). In 
addition, the CV levels of the MR+ NC sera of 
the last two groups were significantly different 
from PD CV levels (P<O*OOOOl). In all patients, 
the significances calculated for CV were always 
better than those found for the individual 
markers included into the CV formula (data not 
shown). The CV was not correlated to histology, 
age or sex. On the contrary, CV was related 
to the pre-treatment stage of the patients, 
increasing from Stage 1 to Stage IV (P=O.O006). 
Discussion 
The present study was intended to evaluate 
whether a statistical procedure could optimize 
the use of a panel of tumour markers, and 
provide a practical test for monitoring the 
response to chemotherapy in NSCLC patients. 
For this purpose, four tumour markers, 
routinely determined for lung cancer follow-up 
(7-l 1,13,19-22), were selected and their pre- and 
post-treatment levels were elaborated by means 
of discriminant analysis. 
This approach is currently applied in tax- 
onomy and epidemiology. The fundamental goal 
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FIG. 1 Discriminant analysis performed on 74 non- 
small cell lung cancer patients (f , generation group; 
validation group) classified as 36 progressive 
diseases (PD) or 38 non-progressive diseases (NPD) 
at the restaging time 0, axis). The NPD patients 
included two complete responses (CR), five partial 
responses (PR), six minor responses (MR) and 25 
no changes (NC). A canonic variable (CV, x axis) 
has been generated, able to correctly classify 65 of 
74 subjects (87.8%). Variables included in the CV, 
after logarithmic transformation, were tissue 
polypeptide antigen (TPA) and carcino-embryonic 
antigen values plus the post-treatment/pre-treatment 
ratios of TPA and neuron-specific enolase. 
with which the method is concerned is the allo- 
cation of an individual to one of two or more 
distinct groups. This allocation is obtained on 
the basis of linear combination of variable 
measurements made on the individuals, that will 
discriminate between the a p’iori defined groups, 
minimizing the misclassification rate. Several 
studies are reported in the medical literature in 
different fields employing this method (23-27). 
In the present study, the CV was generated 
including TPA values, TPA ratios, NSE ratios 
and CEA levels as useful variables for the final 
classification of the patients as PDs or NPDs. 
It has to be emphasized that NSE was also 
selected as a useful variable. Although this 
enzyme is generally considered to be the best 
marker for small cell lung cancer (SCLC), it has 
also been employed for predicting response to 
chemotherapy in NSCLC patients (28,29). 
Many authors have shown the reliability 
of CYFRA-21.1 as a marker for NSCLC 
(10,20,22,24), but the present analysis excluded 
this cytokeratin from the list of selected vari- 
ables. This occurrence is probably related to the 
lower significant differences of CYFRA-21.1 
values found between the two groups of sub- 
jects, and to the strong correlation with TPA 
and CEA. 
Of the 43 subjects in the generation group, 
88.4% were correctly distinguished by the jack- 
knifed classification approach (16). A further 
validation was obtained on a second group of 31 
patients, confirming the reliability of this for- 
mula for classifying patients not previously used 
for the CV generation. The analysis of the CV 
distribution among the five different types of 
response (CR, PR, MR, NC and PD), as evalu- 
ated by means of restaging techniques, showed 
that PDs are clearly distinguishable from NC, 
indicating that PD is characterized by an evident 
CV increase. 
Imaging data represent the standard pro- 
cedure for the objective evaluation of therapeutic 
activity of anti-neoplastic drugs. Some of them, 
such as computerized tomographic scan and 
radionuclide bone scan, are extremely reliable 
procedures, but are resource demanding and 
time-consuming for the patient, and therefore 
not used routinely in many peripheral clinical 
centres. On the other hand, chest X-ray is a 
simple, routine and inexpensive test. Neverthe- 
less, the precision of this technique is often 
hampered by lack of measurable lesions when 
the tumour image is obscured by atelectasis, 
pneumonia, pleural effusion and normal 
intrathoracic structures (30). For such cases, 
relatively simple serological tests may be helpful 
to assess the response to chemotherapy. Radio- 
immunological or immunoenzymatic determi- 
nation of tumour markers is now available 
everywhere, and the automatization of these 
tests easily permits their measure in a large 
number of specimens. The increasing quality of 
the reagent standardization produces reliable 
results due to data reproducibility both intra- 
and interassay. 
On this basis, and until more powerful tumour 
markers are developed, this CV seems to be 
useful as a monitoring test to detect disease 
progression and promptly prevent continuation 
of ineffective toxic treatment, especially in 
patients with poor cardiorespiratory functions, 
often worsened by chemotherapy. 
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Due to the small number of patients enrolled 
in this study, a larger group of NSCLC subjects 
will be analysed in the future. Therefore, another 
study has been planned to confirm the promising 
results of the present work. Also, the authors 
will evaluate whether the use of a tumour marker 
panel, determined after the first cycle of chemo- 
therapy, may allow an earlier detection of 
relapse, preceding the clinical evidence of 
tumour recurrence. In addition, this future study 
will explore a possible relationship between CV 
levels and patient survival. 
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